Progressive Abduction Loading Therapy
Summary
This study attempts to minimize the development of a common movement impairment following stroke known as "flexion synergy" that makes it extremely difficult to reach outward with the arm. Participants with acute/subacute stroke will receive one of two study interventions in addition to their prescribed therapies in both inpatient rehabilitation and day-rehab. Participants will be followed for 1 year.
Study Design
Conditions
Stroke, Acute
Intervention
Abduction Loading, Supported Reaching
Location
Department of Physical Therapy and Human Movement Sciences
Chicago
Illinois
United States
60611
Status
Not yet recruiting
Source
Northwestern University
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT04118998
- ClinicalTrials.gov processed this data on October 11, 2019
Published on BioPortfolio: 2019-10-15T11:11:29-0400
Clinical Trials
Ticagrelol Versus Aspirin in Ischemic Stroke
There is a debate whether ticagrelor is superior to aspirin in treating patients with ischemic stroke or not, most of the studies examine the effect of both drugs within 24 hours of acute ...
The primary objective of the study is to compare the effect of 90-day treatment with ticagrelor (180 mg [two 90 mg tablets] loading dose on Day 1 followed by 90 mg twice daily maintenance ...
Neuromuscular and Biomechanical Control of Lower Limb Loading in Individuals With Chronic Stroke
Stroke is the leading cause of long-term disability in the U.S. Individuals with hemiparesis due to stroke often have difficulty bearing weight on their legs and transferring weight from o...
The postoperative shoulder rehabilitation in an abduction brace after rotator cuff reconstruction of the shoulder is crucial for a successful healing of the reconstruction. In this study ...
The project targets stroke survivors to investigate the effect of augmented feedback (using robotic force cues and visual feedback) on their upper limb reaching patterns and trunk compensa...
PubMed Articles
Do acute stroke patients develop hypocapnia? A systematic review and meta-analysis.
Carbon dioxide (CO) is a potent cerebral vasomotor agent. Despite reduction in CO levels (hypocapnia) being described in several acute diseases, there is no clear data on baseline CO values in acute s...
Plasma CLEC-2 as a Predictor of Death and Vascular Events in Patients with Acute Ischemic Stroke.
CLEC-2 is a C-type lectin-like receptor with the prominent involvement in platelet activation, which was increased in coronary heart disease (CHD) and acute ischemic stroke (AIS) and was associated wi...
Stroke-associated pneumonia (SAP) is an important cause of poststroke morbidity and mortality. Several clinical risk scores predict the risk of SAP. In this study, we used the A DS score (age, at...
Elevated high-sensitive cardiac troponin (hs-cTn) can be found in more than 50% of the patients with acute ischemic stroke. The observational TRoponin ELevation in Acute ischemic Stroke (TRELAS) study...
Acute stroke is the third leading cause of death in Taiwan. Although statin therapy is widely recommended for stroke prevention, little is known about the epidemiology of statin therapy after acute is...
Medical and Biotech [MESH] Definitions
Stroke Rehabilitation
Restoration of functions to the maximum degree possible in a person or persons suffering from a stroke.
Karoshi Death
Sudden death from overwork, most often as a result of acute CARDIOVASCULAR STROKE.
Duane Retraction Syndrome
A syndrome characterized by marked limitation of abduction of the eye, variable limitation of adduction and retraction of the globe, and narrowing of the palpebral fissure on attempted adduction. The condition is caused by aberrant innervation of the lateral rectus by fibers of the oculomotor nerve. There are three subtypes: type 1 (associated with loss of abduction), type 2 (associated with loss of adduction), and type 3 (loss of abduction and adduction). Two loci for Duane retraction syndrome have been located, one at chromosome 8q13 (DURS1) and another at chromosome 2q31(DURS2). It is usually caused by congenital hypoplasia of the abducens nerve or nucleus, but may rarely represent an acquired syndrome. (Adams et al., Principles of Neurology, 6th ed, p271; Miller et al., Clinical Neuro-Ophthalmology, 4th ed, p691)
Stroke, Lacunar
Stroke caused by lacunar infarction or other small vessel diseases of the brain. It features hemiparesis (see PARESIS), hemisensory, or hemisensory motor loss.
Stroke
A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
More From BioPortfolio on "Progressive Abduction Loading Therapy"
Quick Links
Advanced Search |
Login |
Subscribe |
RSS 
BioPortfolio Twitter Channels (200+ Accounts)
LinkedIn